

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

**CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025
WITH
INDEPENDENT AUDITOR'S REVIEW REPORT**

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025
(Expressed in Saudi Riyals, unless otherwise stated)

INDEX	PAGE
Independent auditor's report on review of condensed interim financial statements	-
Condensed statement of financial position	1
Condensed statement of profit or loss and other comprehensive income	2
Condensed statement of changes in equity	3
Condensed statement of cash flows	4 – 5
Notes to the condensed interim financial statements	6 – 16



KPMG Professional Services Company

16th Floor, Al Barghash Tower
6189 Prince Turki Road, Al Corniche
P.O. Box 4803
Al Khobar, 34412 - 3146
Kingdom of Saudi Arabia
Commercial Registration No 2051062328

Headquarters in Riyadh

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية

الطابق ١٦، برج البرغاش
٦١٨٩ طريق الأمير تركي، الكورنيش
ص.ب ٤٨٠٣
الخبير ٣١٤٦ - ٣٤٤١٢
المملكة العربية السعودية
سجل تجاري رقم ٢٠٥١٠٦٢٣٢٨

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed interim financial statements

To the shareholders of Al Moosa Health Company (A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 30 June 2025 condensed interim financial statements of Al Moosa Health Company ("the Company") which comprises:

- the condensed statement of financial position as at 30 June 2025;
- the condensed statement of profit or loss and other comprehensive income for the three and six-month period ended 30 June 2025;
- the condensed statement of changes in equity for the six-month period ended 30 June 2025;
- the condensed statement of cash flows for the six-month period ended 30 June 2025; and
- the notes to the condensed interim financial statements.

Management is responsible for the preparation and presentation of these condensed interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of condensed interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

KPMG Professional Services Company, a professional closed joint stock company registered in the Kingdom of Saudi Arabia with a paid-up capital of SAR110,000,000 and a non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. Commercial Registration of the headquarters in Riyadh is 1010425494.

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية، شركة مهنية مساهمة مغلقة، مسجلة في المملكة العربية السعودية، رأس مالها (١١٠,٠٠٠,٠٠٠) ريال سعودي مدفوع بالكامل، وهي عضو غير شريك في الشبكة العالمية لشركات كي بي إم جي المستقلة والتابعة لـ كي بي إم جي العالمية المحدودة، شركة انجليزية محدودة بضمنان. رقم السجل التجاري للمركز الرئيسي في الرياض هو ١٠١٠٤٢٥٤٩٤.

Independent auditor's report on review of condensed interim financial statements (continued)

To the shareholders of Al Moosa Health Company (A Saudi Joint Stock Company)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 June 2025 condensed interim financial statements of Al Moosa Health Company are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

For KPMG Professional Services Company



Mohammed Najeeb Alkhelaiwi
License no. 481



Al Khobar,
Date: 6 August 2025G
Corresponding to: 12 Safar 1447H

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF FINANCIAL POSITION


AS AT 30 JUNE 2025


(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 June 2025 (Unaudited)	31 December 2024 (Audited)
ASSETS			
Non-current assets			
Property and equipment	3	2,103,035,573	1,894,434,303
Intangible assets		9,415,183	8,385,611
Equity-accounted investee	4	8,987,263	8,990,066
Right-of-use assets		13,394,201	16,612,677
Total non-current assets		2,134,832,220	1,928,422,657
Current assets			
Inventories		77,404,774	68,263,521
Accounts receivable	5	651,158,326	484,347,051
Investments	6	86,745,844	-
Advances, prepayments and other current assets		32,308,133	34,205,858
Cash and cash equivalents		73,187,909	38,201,085
Total current assets		920,804,986	625,017,515
Total assets		3,055,637,206	2,553,440,172
EQUITY AND LIABILITIES			
Equity			
Share capital	7	443,035,800	350,000,000
Share premium	7	1,088,518,860	-
Retained earnings		376,885,614	367,735,728
Total equity		1,908,440,274	717,735,728
Liabilities			
Non-current liabilities			
Long term loans	8	580,467,141	1,148,996,108
Lease liabilities		7,286,380	8,252,166
Employees' benefits		123,220,272	115,629,704
Total non-current liabilities		710,973,793	1,272,877,978
Current liabilities			
Accounts payable		299,098,467	253,637,270
Accruals and other current liabilities		41,996,511	44,007,339
Derivative financial instruments		1,152,801	218,746
Refund liabilities	10.1	67,604,207	60,280,719
Long term loans – current portion	8	16,677,785	123,794,224
Short term borrowings		-	65,000,000
Lease liabilities – current portion		5,568,240	7,023,256
Zakat provision	9	4,125,128	8,864,912
Total current liabilities		436,223,139	562,826,466
Total liabilities		1,147,196,932	1,835,704,444
Total equity and liabilities		3,055,637,206	2,553,440,172

These condensed interim financial statements were authorized for issue by the Board of Directors and approved by:


Malek Al Moosa
(Chief Executive Officer)


Abdulaziz Al Moosa
(Chairman of Board of Directors)


Shailesh Chander
(Chief Financial Officer)

The accompanying notes 1 to 20 on pages 6 to 16 form an integral part of these condensed interim financial statements.

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)


**CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

	Note	For the three-month period ended		For the six-month period ended	
		30 June 2025 (Unaudited)	30 June 2024 (Unaudited)	30 June 2025 (Unaudited)	30 June 2024 (Unaudited)
Revenue	10	348,965,031	284,591,688	671,945,754	561,748,878
Cost of revenue		(236,877,109)	(209,425,690)	(461,070,646)	(408,038,657)
Gross profit		112,087,922	75,165,998	210,875,108	153,710,221
General and administration expenses		(49,671,258)	(45,827,295)	(92,996,075)	(86,432,704)
Selling and marketing expenses		(7,352,057)	(7,330,260)	(13,868,748)	(13,283,280)
Expected credit loss on accounts receivable		(919,974)	(1,106,162)	(1,808,837)	(2,450,191)
Other income	11.1	2,097,010	2,813,096	6,751,091	5,677,888
Other expenses	11.2	(1,831,231)	-	(4,395,575)	-
Operating profit		54,410,412	23,715,377	104,556,964	57,221,934
Finance cost		(3,989,922)	(24,175,343)	(10,607,248)	(41,643,463)
Finance income	12	2,159,712	-	6,676,965	-
Net finance cost		(1,830,210)	(24,175,343)	(3,930,283)	(41,643,463)
Share of (loss) / profit of equity-accounted investee		(44,746)	17,414	(2,803)	305,694
Profit / (loss) before zakat		52,535,456	(442,552)	100,623,878	15,884,165
Zakat (expense) / adjustment for the period	9	(762,564)	(817,594)	2,277,280	(3,417,594)
Profit / (loss) for the period		51,772,892	(1,260,146)	102,901,158	12,466,571
Other comprehensive income					
<i>Items that will not be reclassified to profit or loss in subsequent period</i>					
Re-measurement of defined benefit obligations		1,912,580	1,538,208	2,005,760	1,538,208
Other comprehensive income for the period		1,912,580	1,538,208	2,005,760	1,538,208
Total comprehensive income for the period		53,685,472	278,062	104,906,918	14,004,779
Earnings per share:					
Basic and diluted earnings / (loss) per share	14	1.17	(0.04)	2.34	0.36


Malek Al Moosa
(Chief Executive Officer)


Abdulaziz Al Moosa
(Chairman of Board of Directors)


Shailesh Chander
(Chief Financial Officer)

The accompanying notes 1 to 20 on pages 6 to 16 form an integral part of these condensed interim financial statements.

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

**CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

	Share capital	Proposed share capital	Statutory reserve	Share premium	Retained earnings	Total
Balance at 1 January 2024 (Audited)	1,000,000	349,000,000	300,000	-	305,703,471	656,003,471
<i>Total comprehensive income for the year</i>						
Profit for the period	-	-	-	-	12,466,571	12,466,571
Other comprehensive income for the period	-	-	-	-	1,538,208	1,538,208
Total comprehensive income for the period	-	-	-	-	14,004,779	14,004,779
Transfer of proposed capital	349,000,000	(349,000,000)	-	-	-	-
Transfer of statutory reserve	-	-	(300,000)	-	300,000	-
Dividend (note 16)	-	-	-	-	(36,912,203)	(36,912,203)
Balance as on 30 June 2024 (Unaudited)	350,000,000	-	-	-	283,096,047	633,096,047
Balance at 1 January 2025 (Audited)	350,000,000	-	-	-	367,735,728	717,735,728
<i>Total comprehensive income for the period</i>						
Profit for the period	-	-	-	-	102,901,158	102,901,158
Other comprehensive income for the period	-	-	-	-	2,005,760	2,005,760
Total comprehensive income for the period	-	-	-	-	104,906,918	104,906,918
Issue of new shares (note 7)	93,035,800	-	-	1,088,518,860	-	1,181,554,660
Initial public offering cost	-	-	-	-	(40,377,557)	(40,377,557)
Dividend paid (note 16)	-	-	-	-	(55,379,475)	(55,379,475)
Balance as on 30 June 2025 (Unaudited)	443,035,800	-	-	1,088,518,860	376,885,614	1,908,440,274


Malek Al Moosa
(Chief Executive Officer)


Abdulaziz Al Moosa
(Chairman of Board of Directors)


Shailesh Chander
(Chief Financial Officer)

The accompanying notes 1 to 20 on pages 6 to 16 form an integral part of these condensed interim financial statements.

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF CASH FLOWS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 June 2025 (Unaudited)	30 June 2024 (Unaudited)
Cash flows from operating activities:			
Profit before zakat		100,623,878	15,884,165
<u>Adjustments for:</u>			
Depreciation on property and equipment	3	41,042,982	36,563,027
Amortization on intangibles		886,860	1,142,728
Depreciation on right-of-use assets		3,218,476	2,102,742
(Gain) / loss on disposal of property and equipment		(16,800)	(67,000)
Interest expense on long term loans		10,759,844	41,643,463
Interest expenses on lease liability		351,167	26,336
Employees' defined benefit expense		13,837,302	12,021,813
Provision for impairment loss on accounts receivable	5	1,808,837	2,450,191
Share of loss / (profit) of equity-accounted investees		2,803	(305,695)
Unwinding of interest free loan and transaction cost		430,292	511,500
Loss on investments a fair value through profit or loss	11.2	3,254,156	-
Amortization of transaction cost		-	63,529
		176,199,797	112,036,799
Changes in:			
Accounts receivable		(168,620,112)	(29,262,425)
Inventories		(9,141,253)	(5,970,307)
Advances, prepayments and other current assets		1,897,725	(8,275,947)
Accounts payable		45,461,197	38,509,641
Accruals and other current liabilities		(2,010,828)	6,543,643
Refund liabilities		7,323,488	18,677,263
Cash generated from operations		51,110,014	132,258,667
Interest paid on loans		(14,259,333)	(34,926,322)
Interest paid on lease liability		(351,167)	-
Employees benefits paid		(4,240,974)	(2,400,984)
Zakat paid	9	(2,462,504)	(3,237,715)
Net cash from operating activities		29,796,036	91,693,646
Cash flows from investing activities:			
Additions to property and equipment		(249,644,564)	(107,612,050)
Additions to intangible assets		(1,916,432)	(568,114)
Proceeds from disposal of property and equipment		17,112	75,031
Purchase of the investments	6.2	(190,000,000)	-
Redemption of investments	6.2	100,000,000	-
Net cash used in investing activities		(341,543,884)	(108,105,133)
Cash flows from financing activities:			
Proceeds from loans and borrowings		-	85,589,265
Repayment of loans and borrowings		(736,642,154)	(52,843,067)
Dividend paid	16	(55,379,475)	(14,008,629)
Principle payment of lease liability		(2,420,802)	(1,616,013)
Proceeds from further issue of shares		1,181,554,660	-
Payment of initial public offering related cost		(40,377,557)	-
Net cash generated from financing activities		346,734,672	17,121,556

ALMOOSA HEALTH COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED STATEMENT OF CASH FLOWS (CONTINUED)
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025
(Expressed in Saudi Riyals, unless otherwise stated)


	<u>Note</u>	<u>30 June 2025</u> <u>(Unaudited)</u>	<u>30 June 2024</u> <u>(Unaudited)</u>
Net increase in cash and cash equivalents		34,986,824	710,069
Cash and cash equivalents at beginning of the period		38,201,085	15,838,943
Cash and cash equivalents at end of the period		73,187,909	16,549,012
Non-cash transactions:			
Dividend in kind		-	22,903,574
Investment in associate		-	(7,800,000)



Malek Al Moosa
(Chief Executive Officer)



Abdulaziz Al Moosa
(Chairman of Board of Directors)



Shailesh Chander
(Chief Financial Officer)

The accompanying notes 1 to 20 on pages 6 to 16 form an integral part of these condensed interim financial statement

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

1. GENERAL INFORMATION

Almoosa Health Company (the "Company") is a Saudi joint stock company registered in the Kingdom of Saudi Arabia under Commercial Registration number 2252022248 dated 6 Shaban 1435H (4 June 2014) and unified number 7011046732. The principal activities of the Company are to act as a private healthcare provider, storing medical items and selling medicine, cosmetics and disposable medical items. The Company's registered office is in Al-Ahsa, Kingdom of Saudi Arabia.

The shareholders of the Company in their extraordinary general meeting have passed a resolution on 16 Shawwal 1445H (corresponding to 25 April 2024) for the increase of Company's capital from SR 350 million to SR 443.04 million divided into 44.30 million shares of equal nominal value of SR. 10 each, by way of an offering of 9.30 million new shares to the public after the approval of the Capital Market Authority and the Saudi Stock Exchange ("Tadawul"), in accordance with the rules and procedures stipulated in the Capital Market Law ("CMA") and the Executive Regulations issued by the CMA. The shares to public were issued at premium of SR 117 per share.

The capital increase and public offering were conducted in compliance with the Capital Market Law ("CMA") and its Executive Regulations, following the approval of the Capital Market Authority and the Saudi Stock Exchange ("Tadawul"). After obtaining the necessary approvals, the Company issued the shares to the public and was successfully listed on Tadawul on 7 January 2025.

The condensed interim financial statements of the Company include activities and results of the following branches having commercial registrations, also assets and liabilities of these are included in these condensed interim financial statements:

Branch Name	Commercial Registration No.	Registration Date	Location
AlMoosa Medical Pharmacy	2252023498	9 Sha'aban 1415H -10 January 1995	Al-Ahsa
Abdul Aziz AlMoosa Drug Store	2252053792	22 Ramadan 1434H -30 July 2013	Al-Ahsa
Almoosa Hospital Medical Consumables Warehouse	2252069957	28 Rabia'l Thani 1439H - 15 January 2018	Al-Ahsa
Almoosa Specialist Hospital Company	2051241163	13 Ramadan 1443 H - 14 April 2022	Al-Ahsa
Almoosa Gym	2031112804	5 Safar 1445 H - 21-Aug-2023	Al-Ahsa
Almoosa for rehabilitation and LTC	2031110416	04 Safar 1444 H - 31 August 2022	Al-Ahsa
The Leaf Kitchen	2252106494	8 Shawal 1443 H - 9 May 2022	Al-Ahsa

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

2.1 Statement of compliance

These condensed interim financial statements have been prepared in accordance with International Accounting Standard IAS 34 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are issued by Saudi Organization for Chartered and Professional Accountants ("SOCPA") and should be read in conjunction with the Company's last annual Financial Statements for the year ended 31 December 2024. These do not include all of the information normally required for a complete set of Financial Statements; however, accounting policies and selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since 31 December 2024. The results of the six-month period ended might not be the indicator of full year results of the Company.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES (Continued)

2.2 Basis of preparation

These condensed interim financial statements have been prepared on a historical cost basis except for derivative financial instruments, investments at fair value through profit or loss which are measured at fair value and employees' end-of-service benefits obligation which is measured at the present value of the obligations as explained in the relevant accounting policy.

2.3 Functional and presentation currency

These condensed interim financial statements are presented in Saudi Riyals (SR) which is the Company's functional currency. All financial information presented in these condensed interim financial statements have been rounded off to the nearest Saudi Riyals, unless otherwise stated.

2.4 Use of judgements and estimates

In preparing these condensed interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

2.5 Material accounting policies

The accounting policies applied in these condensed interim financial statements are the same as those applied in the Company's annual financial statements as at and for the year ended 31 December 2024.

2.6 New standards, amendments and interpretations

New and revised standards with no material effect on the condensed interim financial statements:

The following revised IFRSs have been adopted. The application of these revised IFRSs did not have any material impact on the amounts reported for current and prior periods.

- Lack of Exchangeability – Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates, effective for annual periods beginning on or after 1 January 2025.

However, these amendments did not have an impact on the condensed interim financial statement of the Company.

New and revised standards issued but not yet effective:

The amendments to existing standards that are issued, but not yet effective, up to the date of issuance of the Company's condensed interim financial statements are disclosed below. The Company intends to adopt these amendments to existing standards, if applicable, when they become effective:

- Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, effective for annual periods beginning on or after 1 January 2026.
- Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7, effective for annual periods beginning on or after 1 January 2026.
- IFRS 18 Presentation and Disclosure in Financial Statements, effective for annual periods beginning on or after 1 January 2027.
- IFRS 19 Subsidiaries without Public Accountability: Disclosures, effective for annual periods beginning on or after 1 January 2027.
- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture – Amendments to IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures, effective date to be determined.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**
(Expressed in Saudi Riyals, unless otherwise stated)

3. PROPERTY AND EQUIPMENT

The movement of property and equipment is as follows:

	30 June 2025	31 December 2024	30 June 2024
	(Unaudited)	(Audited)	(Unaudited)
Carrying value at the beginning of the period /year	1,894,434,303	1,743,602,369	1,743,602,369
Additions (note 3.1)	249,644,564	257,267,447	107,612,050
Disposals, net of accumulated depreciation	(312)	(1,249,681)	(30,711,602)
Depreciation for the period /year	(41,042,982)	(74,482,258)	(36,563,027)
Transfer to equity-accounted investees	-	(7,800,000)	-
Dividend in kind	-	(22,903,574)	-
Carrying value at the end of the period /year (note 3.2)	2,103,035,573	1,894,434,303	1,783,939,790

3.1 The additions to property and equipment include capital work-in-progress of SAR 217.34 million (31 December 2024: SAR 303 million and 30 June 2024: SAR 86.12 million), primarily related to the Al Khobar and Al Hofuf hospitals. During the period, borrowing costs on various long-term loans were also capitalized, amounting to SAR 12.5 million (31 December 2024: SAR 21 million and 30 June 2024: SAR 10.44 million).

3.2 The carrying value construction work-in-progress amounting to SR 536.36 million (31 December 2024: SR 319.02 million and 30 June 2024: SAR 271.53 million). It represents costs incurred in relation to Al Khobar hospital, Al Hofuf hospital, medical centers and other projects of the Company, which are currently under construction.

4. EQUITY-ACCOUNTED INVESTEE

The investment in equity-accounted investee represents a 25% ownership in Oryx Isotopes Company ("the associate"), a Limited Liability Company registered on 13/1/1442H corresponding to 1 September 2020G in Dammam, Kingdom of Saudi Arabia with a share capital of SR 500,000. The principal activities of the Company are manufacturing pharmaceuticals for human use and the production of radioactive isotopes.

5. ACCOUNTS RECEIVABLE

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Accounts receivable – trade	657,297,309	489,488,169
Less: allowance for expected credit losses	(6,138,983)	(5,141,118)
	651,158,326	484,347,051

Movement in the allowance for expected credit losses is as follows:

	30 June 2025	31 December 2024	30 June 2024
	(Unaudited)	(Audited)	(Unaudited)
Balance at the beginning of the period / year	5,141,118	6,708,353	6,708,353
Allowance for expected credit losses during the period / year	1,808,837	4,406,741	2,450,191
Doubtful debts written off during the period / year	(810,972)	(5,973,976)	(4,381,652)
Balance at the end of the period / year	6,138,983	5,141,118	4,776,892

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

6. INVESTMENTS

	Note	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Investment at amortised cost	6.1	40,000,000	-
Investment at fair value through profit or loss	6.2	46,745,844	-
Balance at the end of the period / year		86,745,844	-

6.1 Investment at amortised cost

The Company has made an investment of SR 40 million comprising 40 Sukuks certificates amounting to SR 1 million each. The Sukuks carry a fixed rate of commission settled by the bank each quarter.

6.2 Investment at fair value through profit or loss

The Company has made the investment in Mutual funds and Murabaha funds during the period. The Company classifies those quoted equity security investments at FVTPL for which it has not elected to recognize fair value gains and losses through other comprehensive income at initial recognition. The movement in FVTPL investments is set out below;

	30 June 2025 (Unaudited)	31 December 2024 (Audited)	30 June 2024 (Unaudited)
Balance at the beginning of the period / year	-	-	-
Additions during the period / year	150,000,000	-	-
Redemption during the period / year	(100,000,000)	-	-
Realized gain on redemption	1,258,938	-	-
Unrealized loss	(4,513,094)	-	-
Net loss (note 11.2)	(3,254,156)	-	-
Balance at the end of the period	46,745,844	-	-

7. SHARE CAPITAL

The authorized, issued and fully paid share capital of the Company is divided into 44.3 million shares (31 December 2024: 35 million shares) of SR 10 each.

During the year ended 31 December 2024, the shareholders of the Company in their extraordinary general meeting dated 25 April 2024, approved the increase of the Company's share capital from SR 350 million to SR 443.04 million divided into 44.30 million shares of equal nominal value of SR. 10 each and premium of SR 117 each, by way of an offering of 9,303,580 new shares to the public with total share premium of SAR 1,088.52 million. The proposed capital was increased after approval of CMA for the Initial public Offering (IPO). The shares were issued to the public on 7 January 2025. Pursuant to the Company's listing and share capital increase, the amended By-laws and Commercial Registration were submitted to the Ministry of Commerce for approval, following the shareholders' approval at the Annual General Meeting held on 20 May 2025.

8. LONG TERM LOANS

	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Current		
Loans from commercial banks	10,243,378	112,333,331
Loans from Ministry of Finance	2,843,067	2,843,067
Accrued interest expense	3,591,340	8,617,826
	16,677,785	123,794,224

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

8. LONG TERM LOANS (Continued)

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Non- current		
Loans from commercial banks	572,957,534	1,139,666,667
Loans from Ministry of Finance	8,529,198	11,372,265
Less: deferred income on loan from MoF	(1,019,591)	(1,449,883)
Less: amortization of transaction cost	-	(592,941)
	580,467,141	1,148,996,108

Loans from Commercial Banks

The Company obtained loan facilities from various local commercial banks. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin.

Loans from Ministry of Finance

In 2010, the Company entered into a loan agreement for SR 42.6 million with Ministry of Finance to finance the construction of hospital building. The loan is repayable in equal annual instalments of SR 2.8 million each which commenced from 2015 and will continue up to 2030.

The Company is required to comply with certain covenants under the loan facility agreements mentioned above. A future breach of covenants may lead to renegotiation. The covenants are timely monitored, in case of potential breach, actions are taken by management to ensure compliance. As of 30 June 2025, there is no non-compliance of loan covenants from banks, and accordingly these loans were not reclassified to current liabilities.

During the period the finance cost has reduced significantly, mainly due to repayments amounting to SAR 737 million.

Following are the combined aggregate amounts of future maturities representing principal amounts of the term loans as at:

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Within one year	13,086,446	115,176,400
Later than one year but not later than five years	571,243,352	909,663,930
Later than five years	10,243,379	241,375,000
	594,573,177	1,266,215,330

9. ZAKAT PRVISION

The movement in zakat provision is:

	30 June 2025	31 December 2024	30 June 2024
	(Unaudited)	(Audited)	(Unaudited)
Balance at the beginning of the period / year	8,864,912	3,630,266	3,630,266
Charge for the period / year	1,525,128	8,427,266	3,417,594
Prior year adjustment	(3,802,408)	-	-
	(2,277,280)	8,427,266	3,417,594
Paid during the period / year	(2,462,504)	(3,192,620)	(3,237,715)
Balance at the end of the period / year	4,125,128	8,864,912	3,810,145

The Company has submitted its zakat returns up to year 2024 and has obtained the required certificates and official receipts, however, all returns since inception are still under ZATCA review. The reversal of zakat was made based on the actual zakat return filed with the ZATCA, which resulted in a lower zakat liability than previously estimated.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

10. REVENUE

The Company primarily generates revenue from contract with customers from:

- Services relating to inpatient and outpatient; and
- Sale of pharmaceutical goods.

Disaggregation of revenue

In the following table, revenue from contracts with customers is disaggregated by service lines and timing of revenue recognition.

	For the period ended	
	30 June 2025	30 June 2024
	(Unaudited)	(Unaudited)
Revenue by service lines		
Medical services	443,753,758	370,254,944
Pharmaceuticals	152,357,315	129,445,089
Rehabilitation	75,834,681	62,048,845
	671,945,754	561,748,878
Timing of revenue recognition		
Medical services and pharmaceuticals sales transferred at a point in time	312,929,374	252,491,235
Medical services transferred over time	359,016,380	309,257,643
	671,945,754	561,748,878

Revenue from medical services and rehabilitation is recognized at a point in time as well as overtime based on the underlying nature of services provided.

The following table provides information about contract assets and refund liability from contracts with customers:

	As at	
	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Refund liability (note 10.1)	67,604,207	60,280,719

10.1 REFUND LIABILITY

Certain contracts provide for discounts comprising retrospective volume discounts granted to insurance companies on attainment of certain admission levels / certain levels of patient visits. The retrospective volume discounts give rise to variable consideration. Variable consideration is recognised as revenue to the extent that it is highly probable that it will not reverse. Discounts are accrued over the course of the period based on the estimates of the level of business expected using single most likely amount method. This is adjusted at the end of the period to reflect actual volumes. Volume discounts are recorded as a reduction in revenue and liabilities are created based on these estimates.

11.1 OTHER INCOME

	For the period ended	
	30 June 2025	30 June 2024
	(Unaudited)	(Unaudited)
Human Resource Development Fund (HRDF) income	5,325,858	4,639,580
Scientific support income	339,752	379,098
Training courses income	378,297	260,414
Cafeteria income	55,056	282,849
Gain on disposal of property and equipment	16,800	67,000
Others	635,328	48,947
	6,751,091	5,677,888

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

11.2 OTHER EXPENSES

	For the period ended	
	30 June 2025	30 June 2024
	(Unaudited)	(Unaudited)
Fair value loss on investments at fair value through profit or loss (note 6.2)	3,254,156	-
Initial public offering cost	1,141,419	-
	4,395,575	-

12. FINANCE INCOME

	For the period ended	
	30 June 2025	30 June 2024
	(Unaudited)	(Unaudited)
Income from time deposits	5,664,298	-
Income from Sukuks	1,012,667	-
	6,676,965	-

13. RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include the Company's ultimate controlling person (Abdulaziz Abdullah AlMoosa), other shareholders, associated companies and their shareholders, key management personnel, Board of Directors, and entities controlled, jointly controlled or significantly influenced by such parties. Terms and conditions of these transactions are approved by the Company's management.

The following are the nature and transactions with the related parties during the period and its related balances as at end of the period.

Nature of transaction	Relationship	For the six-month period ended	
		30 June 2025	30 June 2024
Initial public offering cost	Previous shareholders	17,304,666	-
Supply of services	Under common ownership of the	606,694	799,688
Purchase of goods	Company's shareholder	1,377,404	690,707

a) Due to related party

The breakdown of the amounts due to related party is as follows:

	30 June 2025	31 December 2024
	(Unaudited)	(Audited)
Abdulaziz bin Abdullah Al Moosa Investment Company	1,429,168	-

Amounts due to a related party principally include balances related to the above-mentioned initial public offering cost that is incurred by the company on behalf of the shareholder.

b) Compensation to key management personnel

Key management includes the Board of Directors (executive and non-executive) and all members of Company's management. The compensation paid or payable to key management for employee services is shown below:

	Six-month period ended 30 June 2025	Six-month period ended 30 June 2024
	(Unaudited)	(Unaudited)
Short-term benefits	5,321,033	5,346,033
Termination benefits	328,942	323,525
	5,649,975	5,669,558

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

14. EARNINGS PER SHARE

Basic and diluted earnings per share is calculated by dividing the net income for the period attributable to the shareholders of the Company by the weighted average number of outstanding shares during the period. As the Company does not have any dilutive potential shares, the diluted earnings per share is the same as basic earnings per share.

	For the period ended	
	30 June 2025	30 June 2024
	(Unaudited)	(Unaudited)
Profit for the period attributable to the shareholders of the Company	102,901,158	12,466,571
Weighted average number of outstanding shares during the period	43,995,174	35,000,000
Basic and diluted earnings per share	2.34	0.36

15. CONTINGENT LIABILITIES AND COMMITMENTS

Letter of Credits

As of 30 June 2025, the Company's bankers have given letter of credits, on behalf of the Company, amounting to SR 6.03 million (31 December 2024: SR 5.59 million).

Capital commitments

As of 30 June 2025, the Company's capital commitments amounted to SR 187.22 million (31 December 2024: SR 370 million) relating to certain expansion projects.

16. DIVIDENDS

During the period, the shareholders in General Assembly Meeting held on 20 May 2025 approved dividends of SAR 44.3 million (SAR 1 per share) for the year ended 31 December 2024 and SAR 11.08 million (SAR 0.25 per share) for the period ended 31 March 2025 (June 2024: 36.91 million).

17. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT

The Company's principal financial assets include cash and cash equivalents, accounts receivable, investments and certain other receivables that arise directly from its operations. The Company's principal financial liabilities comprise long-term borrowings, lease liabilities, accounts payable and other payables. The main purpose of these financial liabilities is to finance the Company's operations.

Fair values hierarchy

All financial instruments for which fair value is recognized or disclosed are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole, as follows:

Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

There were no changes in the Company's valuation processes, valuation techniques, and types of inputs used in the fair value measurements during the period.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

17. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT (Continued)

Accounting classifications and fair values

The following table shows the carrying value of financial assets and financial liabilities. It does not include the fair value information for financial assets and financial liabilities not measured at fair value as their carrying amount is a reasonable approximation of fair value.

	30 June 2025	31 December 2024
Particulars	(Unaudited)	(Audited)
Financial assets measured at fair value		
Investment at fair value through profit or loss	46,745,844	-
Financial assets measured at amortized cost		
Cash and cash equivalent	73,187,909	38,201,085
Accounts receivable	657,297,309	489,488,169
Investment at amortized cost	40,000,000	-
Other current assets	1,739,443	1,643,631
Total financial assets measured at amortized cost	772,224,661	529,332,885
Total financial assets	818,970,505	529,332,885

	30 June 2025	31 December 2024
Particulars	Carrying value (Unaudited)	Carrying value (Audited)
Financial liabilities measured at fair value		
Derivative financial instruments	1,152,801	218,746
Financial liabilities measured at amortized cost		
Long term loans	597,144,926	1,272,790,332
Short term borrowings	-	65,000,000
Lease liabilities	12,854,620	15,275,422
Accounts payable	299,098,467	253,637,270
Other current liabilities	19,073,163	20,713,302
Total financial liabilities measured at amortized cost	928,171,176	1,627,416,326
Total financial liabilities	929,323,977	1,627,635,072

As at the reporting date all financial assets and financial liabilities, except for derivative financial instruments and investments at fair value through profit or loss, are measured at amortized cost. The carrying value of the financial assets and financial liabilities of the Company approximate their fair value.

Risk management activities

The Company's financial risk management objectives and policies are consistent with those disclosed in the last annual financial statements as at and for the year ended 31 December 2024.

18. SEGMENT REPORTING

Segment reporting is based on the operating (business) segments of the Company. An operating segment is a component of the Company that engages in business activities from which it may earn revenue or incur expenses. An operating segments operating results are reviewed regularly by the chief executive officer of the Company to make the decision about the resources allocated to the segment and assess its performance, and for which discrete financial information is available.

The segment results presented to the Board of Directors include both items directly attributable to each segment and those that can be reasonably allocated. The business segments operate in distinct areas, each facing unique risks and

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025
(Expressed in Saudi Riyals, unless otherwise stated)

18. SEGMENT REPORTING (Continued)

rewards. The reported segments comprise of medical services -focused on delivering medical care and treatment, rehabilitation center for specializing in rehabilitation-related services and pharmacy engaged in the sale of medicines.

	Medical Services	Pharmaceuticals	Rehabilitation	Total
For the period ended 30 June 2025				
Revenue from contract with customers	443,753,758	152,357,315	75,834,681	671,945,754
Gross profit	153,680,071	45,879,824	11,315,213	210,875,108
Allocated income / (expenses)				
Selling and marketing expenses	(9,067,921)	(211,465)	(4,589,362)	(13,868,748)
General and administrative expenses	(62,307,371)	(9,299,607)	(21,389,097)	(92,996,075)
Provision for impairment loss on accounts receivable	(1,194,559)	(410,136)	(204,142)	(1,808,837)
Other income	5,524,008	301,463	925,620	6,751,091
Other expenses	(4,395,575)	-	-	(4,395,575)
Share of profit from equity-accounted investee	(2,803)	-	-	(2,803)
Finance income	6,676,965	-	-	6,676,965
Finance cost	(1,591,087)	-	(9,016,161)	(10,607,248)
Profit / (loss) before zakat	87,321,728	36,260,079	(22,957,929)	100,623,878
Zakat expense for the period	1,503,919	516,351	257,010	2,277,280
Profit / (loss) for the period	88,825,647	36,776,430	(22,700,919)	102,901,158
For the period ended 30 June 2024				
Revenue from contract with customers	370,254,944	129,445,089	62,048,845	561,748,878
Gross profit	91,378,384	40,732,169	21,599,668	153,710,221
Allocated income / (expenses)				
Selling and marketing expenses	(5,977,476)	(2,656,656)	(4,649,148)	(13,283,280)
General and administration expenses	(38,894,717)	(25,929,811)	(21,608,176)	(86,432,704)
Impairment loss on accounts receivable	(1,614,948)	(564,603)	(270,640)	(2,450,191)
Other income	3,742,359	1,308,369	627,160	5,677,888
Share of profit from equity-accounted investee	305,694	-	-	305,694
Finance cost	(22,071,035)	-	(19,572,428)	(41,643,463)
Profit / (loss) before zakat	26,868,261	12,889,468	(23,873,564)	15,884,165
Zakat expense for the period	(2,252,574)	(787,524)	(377,496)	(3,417,594)
Profit / (loss) for the period	24,615,687	12,101,944	(24,251,060)	12,466,571

The assets and liabilities as of 30 June 2025 and 31 December 2024 of the segments are as follows;

As at 30 June 2025

Segment assets	2,145,404,539	45,735,949	864,496,718	3,055,637,206
Segment liabilities	648,995,014	68,273,008	429,928,910	1,147,196,932

As at 31 December 2024

Segment assets	1,683,310,030	38,787,444	831,342,698	2,553,440,172
Segment liabilities	1,134,184,699	66,162,453	635,357,292	1,835,704,444

All of the Company's operating assets and principal activities are located in the Kingdom of Saudi Arabia.

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025**

(Expressed in Saudi Riyals, unless otherwise stated)

19. SUBSEQUENT EVENTS

On 1 August 2025, the Board of Directors, in their meeting, declared a cash dividend of SAR 15.51 million, equivalent to SAR 0.35 per share for the second quarter ended 30 June 2025 (30 June 2024: Nil).

Except for the above there are no other significant subsequent events have occurred from the date of these condensed interim financial statements to the date of approval of these condensed interim financial statements, that would require adjustments or disclosure in these condensed interim financial statements of the Company.

20. APPROVAL OF THE CONDENSED INTERIM FINANCIAL STATEMENTS

These condensed interim financial statements were authorized for issue by the Board of Directors and approved on 7 Safar1447H, corresponding to 1 August 2025G.